Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 4/20 | 0.47 |
| ▸ | GSK3B | P49841 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.43 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.43 |
| ▸ | RGS4 | P49798 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5800712 | 0.80 | HPGD (0.49) | HPGDGSK3AGSK3BKMT2ASMN1; SMN2 | |
| SCHEMBL7466508 | 0.79 | HPGD (0.55) | HPGDGSK3AGSK3BKMT2ASMN1; SMN2 | |
| SCHEMBL7750738 | 0.79 | HPGD (0.51) | HPGDGSK3AGSK3BKMT2ASMN1; SMN2 | |
| SCHEMBL30272686 | 0.77 | HPGD (0.50) | HPGDGSK3AGSK3BKMT2ASMN1; SMN2 | |
| SCHEMBL8985073 | 0.76 | GSK3B (0.67) | HPGDGSK3AGSK3BKMT2ASMN1; SMN2 | |
| SCHEMBL7519636 | 0.75 | KMT2A (0.52) | HPGDGSK3AGSK3BKMT2ACYP3A4 | |
| SCHEMBL10077158 | 0.74 | KDM4E (0.47) | GSK3AGSK3BKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL5482630 | 0.72 | HPGD (0.49) | HPGDGSK3AGSK3BKMT2ACYP3A4 | |
| SCHEMBL25827018 | 0.69 | HPGD (0.57) | HPGDGSK3AGSK3BKMT2ASMN1; SMN2 | |
| SCHEMBL14229126 | 0.69 | CCR2 (0.58) | HPGDGSK3AGSK3BKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016079502-A1 | METAL CHELATING COMPOUNDS FOR USE IN TREATING DISEASES | UNIVERSITY OF NORTHUMBRIA (GB) | 2016-05-26 | — | — | WO | disclosed |
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2013-03-14 | — | — | US | disclosed |
| US-20120329842-A1 | SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-12-27 | — | — | US | disclosed |
| US-20120329842-A1 | SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-12-27 | — | — | US | disclosed |
| WO-2012088283-A1 | SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES | BAYLOR COLLEGE OF MEDICINE (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2011046920-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011046920-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | DDX18, FPR1, DCXR | HPGD 1165/4885GSK3A 4546/4885GSK3B 4387/4885 |
| US-20120329842-A1 | SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, MGAM2, BPGM | HPGD 1211/4885GSK3A 624/4885GSK3B 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.